Neo-Eunomin (Chlormadinone Acetate, Ethinylestradiol)

chlormadinone acetate / ethinylestradiol, the active ingredient in Neo-Eunomin, is a combined estrogen‑progestogen oral contraceptive presented as a tablet/oral tablet for oral use. It prevents pregnancy and helps regulate menstrual cycles in women of reproductive age, and is prescribed for reliable birth control and menstrual cycle management.

GNH USA supplies Neo-Eunomin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality assurance protocols and providing regulatory‑approved documentation for global distribution and reliable logistics support.

Neo-Eunomin, a combined estrogen‑progestogen oral contraceptive, acts on the hormonal regulation of the reproductive system.

- Prevention of pregnancy: provides reliable contraceptive protection when taken as directed. - Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces dysmenorrhea. - Treatment of estrogen‑dependent conditions: may be used under medical supervision for conditions such as endometriosis or acne.

Neo-Eunomin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Spotting or irregular bleeding

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis or pulmonary embolism) - Stroke or transient ischemic attack - Myocardial infarction - Severe allergic reaction (anaphylaxis) - Hepatic adenoma or other serious liver disorders

Before prescribing Neo-Eunomin, clinicians should evaluate several safety considerations.

- Assess cardiovascular risk: review history of thromboembolic disease, hypertension, or smoking. - Screen smoking status: avoid use in women over 35 who smoke heavily. - Evaluate hepatic function: use with caution in patients with liver impairment. - Review concomitant medications: consider potential interactions that may reduce efficacy. - Pregnancy and lactation: discontinue if pregnancy is confirmed and avoid during breastfeeding unless advised. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Neo-Eunomin can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Certain antiretrovirals (e.g., efavirenz): can lower hormone levels and increase risk of breakthrough bleeding. - Anticoagulants (e.g., warfarin): combined use may enhance thrombotic risk.

Moderate Interactions (Monitor Closely): - Other hormonal therapies (e.g., hormone replacement therapy): may increase overall estrogen exposure. - Diuretics: may affect fluid balance and blood pressure. - Antihypertensive agents: may require dose adjustment due to hormonal effects on blood pressure.